including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters ...
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... driven by slower growth in the HIV ...
Gilead Sciences, Inc. (NASDAQ:GILD ... quarter of commercial and operational execution with robust year-over-year revenue performance across HIV, Oncology, and Liver Disease, including 9% growth in ...
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...
Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...
Shanghai Daily on MSN14h
Patients to benefit from major CIIE purchasesMajor purchases of the most advanced medical equipment and consumables, and cooperation on major infectious diseases such as ...
In terms of industry tailwinds, Trump could lessen pressure from the Federal Trade Commission on mergers and acquisitions, ...
Falls: assessment and prevention in older people and people 50 and over at higher risk (update) Draft guidance consultation NICE guideline 28 November 2024 Fenfluramine for treating seizures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback